AsiaMedic Limited FY2025 Financial Results: Strong Growth Driven by Diagnostic Imaging Expansion
AsiaMedic Limited has released its condensed interim consolidated financial statements for the full year ended 31 December 2025, demonstrating robust growth in revenue and profitability, driven primarily by the expansion of its diagnostic imaging segment. This review analyzes key metrics, performance drivers, and strategic developments based strictly on the released financial report.
Key Financial Metrics and YoY/QoQ Performance
| Metric |
2H2025
(Current Half) |
1H2025
(Previous Half) |
2H2024
(Same Half Last Year) |
YoY Change |
QoQ Change |
| Revenue |
\$18.61m |
\$16.62m |
\$15.75m |
+18% |
+12% |
| Profit After Tax |
\$2.05m |
(\$0.62m) |
\$0.75m |
+173% |
nm |
| Earnings Per Share (EPS, cents) |
0.18 |
-0.06 |
0.10 |
+80% |
nm |
| Dividend per Share |
0.00 |
0.00 |
0.00 |
No Change |
No Change |
Notes: ‘nm’ denotes not meaningful due to negative/positive swing. 1H2025 includes a loss, highlighting the sharp recovery in 2H2025.
Historical Performance Trends
- Full-year revenue increased 22% YoY to \$35.22m (FY2025), up from \$28.91m (FY2024).
- Profit after tax for FY2025 was \$1.43m, more than double the \$0.65m recorded in FY2024.
- EPS for the year rose to 0.18 cents (diluted and basic), from 0.09 cents in FY2024.
- Net asset value per share improved to 1.42 cents (Group) from 1.24 cents a year ago.
Exceptional Items and Corporate Actions
- Disposal of Subsidiary: In October 2025, AsiaMedic disposed of its 60% stake in AsiaMedic Astique The Aesthetic Clinic Pte. Ltd. (AATAC), recognizing a net gain of approximately \$0.9m, which positively impacted the bottom line.
- Impairment: An expected credit loss provision of \$1.03m was recognized on a shareholder loan to AATAC post-disposal.
- Share Capital Reduction: The company executed a selective capital reduction in June 2025, cancelling 25 million shares, reducing issued shares to 1,129,522,270 (excluding 100,000 treasury shares).
- No Dividend Declared: The Board did not recommend a dividend, citing the need to conserve cash for expansion, debt servicing, and working capital, as the company remains in an accumulated losses position.
Segment Performance and Business Drivers
- Diagnostic Imaging: The main driver of growth, with segment revenue growing 45% YoY as the new Royal Square Medical Centre Novena ramped up operations.
- Medical Wellness and Health Screening: Remained stable YoY at \$9.6m, reflecting steady demand.
- Primary Healthcare Services: Revenue was steady at \$2.4m.
- Medical Aesthetics: Declined due to the sale of AATAC, with revenue recognized only up to the disposal date.
Balance Sheet and Cash Flow Highlights
- Net Current Assets: Increased to \$8.9m, up from \$8.3m last year.
- Cash and Cash Equivalents: Decreased to \$5.7m (FY2025) from \$8.0m (FY2024) due to capex, debt repayment, and treasury placements.
- Borrowings: Total borrowings fell to \$17.87m (FY2025) from \$21.15m (FY2024), reflecting active loan repayments.
- Operating Cash Flow: Improved to \$3.9m (FY2025) from \$2.5m (FY2024).
Significant Events and Outlook
- Expansion: Successful ramp-up of the Novena diagnostic centre positions AsiaMedic for future growth, with plans to focus on operational efficiency and utilization rates.
- On-site Healthcare: Contribution from this segment is expected to decline as the company did not win the Health Promotion Board school health screening tender for the next period.
- Industry Trends: Management remains cautiously optimistic, citing demographic tailwinds, preventive healthcare demand, and government-led initiatives as positives, but notes competitive pressures and rising costs as ongoing challenges.
- No Further Share Dilution: Aside from employee share options, there were no major dilutive events; outstanding options cover 50.8m shares.
Chairman’s Statement
No direct Chairman’s Statement was included in the report. However, the management commentary on outlook is constructive but cautious, highlighting both growth opportunities and cost pressures. The tone is pragmatic, focusing on operational improvement and prudent capital allocation.
Related Party Transactions and Remuneration
- Purchase of consumables from associate: \$421,800 (FY2025), consistent with prior year.
- No disclosures of director remuneration or unusual fund flows.
Conclusion and Investment Recommendations
Overall Assessment: AsiaMedic Limited delivered a strong financial performance in FY2025, driven by the successful expansion of its diagnostic imaging business and improved operating leverage. The company’s focus on cash preservation, debt reduction, and operational efficiency is prudent given competitive and cost pressures. The absence of a dividend reflects ongoing accumulated losses but also a prudent approach to capital management.
- If you are currently holding AsiaMedic shares: The outlook is cautiously optimistic, and the company is on a growth trajectory with improved profitability and a sound balance sheet. Hold existing positions, but monitor the company for continued profitability, improvements in cash flow, and any changes in dividend policy.
- If you are not currently holding AsiaMedic shares: The company’s turnaround and growth in core diagnostic imaging could make it an attractive entry point for growth-focused investors, especially if it sustains earnings momentum and leverages industry tailwinds. However, the lack of dividends and ongoing accumulated losses may not appeal to income-focused investors.
Disclaimer: This analysis is based solely on information disclosed in the company’s official financial report and does not constitute investment advice. Investors should consider their own financial circumstances and risk tolerance before making investment decisions.
View AsiaMedic Historical chart here
